Company Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer.
It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma.
In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor.
The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products.
It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally.
Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 104 |
| CEO | Michael Rossi |
Contact Details
Address: 202 Carnegie Center, Suite 301 Princeton, New Jersey 08540 United States | |
| Phone | (646)-885-8505 |
| Website | ymabs.com |
Stock Details
| Ticker Symbol | YMAB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001722964 |
| CUSIP Number | 984241109 |
| ISIN Number | US9842411095 |
| Employer ID | 47-4619612 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Rossi | Chief Executive Officer, President and Director |
| Thomas Gad | Founder, Chief Business Officer and Vice Chairman |
| Peter P. Pfreundschuh CPA | Executive Vice President, Chief Financial Officer and Treasurer |
| Joris Wiel Jan Wilms | Senior Vice President and Chief Operating Officer |
| Dr. Torben Lund-Hansen M.Sc., Ph.D. | Senior Vice President and Chief Technology Officer |
| Courtney Dugan | Vice President of Investor Relations |
| John W. LaRocca Esq. | Senior Vice President, General Counsel, Secretary and Chief Legal Officer |
| Dr. Norman D. LaFrance FACNP, FACP, M.D. | Chief Development Officer and Chief Medical Officer |
| Doug Gentilcore | Senior Vice President and Head of DANYELZA Business Unit |
| Natalie Tucker | Senior Vice President and Radiopharmaceutical Business Unit Head |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2025 | 8-K | Current Report |
| May 30, 2025 | ARS | Filing |
| May 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 30, 2025 | DEF 14A | Other definitive proxy statements |
| May 28, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13G | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 29, 2025 | 10-K/A | [Amend] Annual report |
| Mar 7, 2025 | 144 | Filing |